ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: The 1990s and early 2000s saw the success of other treatments aimed at molecular targets, such as imatinib against the BCR-ABL translocation seen in chronic myelogenous leukemia, rituximab (anti-CD20) as a treatment for B-cell lymphomas, and retinoic acid for treatment of PML-RAR fusion acute promyelocytic leukemia (Table 1) [17–21].